Report Sections

See All Reports

  • HP:0002110: Bronchiectasis
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002110: Bronchiectasis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (4)


    Name (Synonyms) Correlation
    drug792 Ciclesonide Wiki 0.41
    drug664 COVID-19 patients Wiki 0.41
    drug790 Cholecalciferol Wiki 0.29
    Name (Synonyms) Correlation
    drug2505 Placebo Wiki 0.03

    Correlated MeSH Terms (8)


    Name (Synonyms) Correlation
    D001987 Bronchiectasis NIH 1.00
    D001469 Barotrauma NIH 0.58
    D004646 Emphysema NIH 0.41
    Name (Synonyms) Correlation
    D017563 Lung Diseases, Interstitial NIH 0.17
    D008171 Lung Diseases, NIH 0.13
    D011024 Pneumonia, Viral NIH 0.07
    D014777 Virus Diseases NIH 0.06
    D011014 Pneumonia NIH 0.03

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0006515 Interstitial pneumonitis HPO 0.17
    HP:0002088 Abnormal lung morphology HPO 0.13
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials


    1 The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults

    Bronchiectasis is clinically characterized by irreversible dilation of the bronchi and bronchioles leading to persistent cough, purulent sputum, and airway flow limitation, which may be accompanied by recurrent exacerbations.It has been increasingly recognized that respiratory viruses are mainly responsible for acute exacerbation of chronic pulmonary diseases, i.e. asthma, chronic obstructive pulmonary disease and cystic fibrosis. However,little is known about the roles of viral infection in driving exacerbations of bronchiectasis.This study aims to identify the frequency of common viral infections and determine the roles that viruses play in acute exacerbations of bronchiectasis.

    NCT01801657
    Conditions
    1. Bronchiectasis
    MeSH:Virus Diseases Bronchiectasis
    HPO:Bronchiectasis

    Primary Outcomes

    Description: Respiratory viruses in the nasal swab and sputum will be identified using the polymerase chain reaction(PCR)technique when clinically stable and during exacerbation.The following viruses will be tested for:influenza A,B(including influenza A H1N1),respiratory syncytial virus(RSV),Enterovirus,Parainfluenza 1-4,Rhinovirus,human Coronaviruses(subtypes OC43、229E、HKU1),human metapneumovirus,adenovirus, human bocavirus,chlamydia,mycoplasma.

    Measure: The prevalence of respiratory virus infection in adults with bronchiectasis during a pulmonary exacerbation and when clinically stable.

    Time: 1 year

    Secondary Outcomes

    Description: Systemic and airway inflammatory cytokines including IL-1β、IL-6、IL-8、TNF-a were measured using a commercial multiplex bead-based assay.

    Measure: The effect of respiratory virus infection on systemic and pulmonary inflammatory markers.

    Time: 1 year

    Description: Spirometric indices in the present study is referred to as forced expiratory vilume in 1s(FEV1),forced vital capacity(FVC).Spirometry tests are carried out using a spirometer (COSMED, QUARK PFT, Italy). All operation procedures meet the joint recommendation by ATS and ERS. A total of at least 3 (not more than 8) spirometric maneuvers are performed, with the variation between the best two maneuvers of <5% or 200ml in FVC and FEV1. The maximal values of FVC and FEV1 are reported.

    Measure: The effect of respiratory virus on lung function

    Time: 1 year

    Description: Type of bacterial infection, also referred to as potentially pathogenic organisms, and bacterial load, as expressed in cfu per mililiter

    Measure: The effect of respiratory virus infection on the bacterial load in bronchiectasis.

    Time: 1 year

    Description: The time from exacerbation onset by which a 3-d moving average was equal to or exceeded the baseline value

    Measure: Time to recovery of respective symptom

    Time: 1 year

    Description: Quality of life in patients with bronchiectasis were measured by St.George Respiratory Questionnaire、Leicester Cough Questionnaire and COPD assessment test during exacerbations,and then compared between virus-postive and virus-negative patients

    Measure: The effect of respiratory virus on quality of life in patients with bronchiectasis

    Time: 1 year

    Measure: To investigate if upper respiratory tract symptoms are associated with viral infections.

    Time: 1 year
    2 SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia

    Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive ventilation (NIV-CPAP) and invasive mechanical ventilation (IMV). Main purpose of this study is to evaluate with non invasive clinical instruments (pletysmography, Diffusion lung capacity for carbon monoxide -DLCO-, six minute walking test and dyspnea scores) and radiological tools (chest X-ray and chest CT scan) the development of medium-to-long term pulmonary sequelae caused by SARS-CoV-2 pneumonia.

    NCT04435327
    Conditions
    1. COVID
    2. Pneumonia, Viral
    3. Barotrauma
    4. Interstitial Lung Disease
    5. Bronchiectasis Adult
    6. Emphysema
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Bronchiectasis Lung Diseases, Interstitial Emphysema Barotrauma
    HPO:Abnormal lung morphology Bronchiectasis Interstitial pneumonitis Interstitial pulmonary abnormality Pneumonia

    Primary Outcomes

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T1 at 6 months from discharge

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T2 at 12 months from discharge

    Secondary Outcomes

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV,%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: Modified Medical Research Council - mMRC > 0 (minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T1 at 6 months from discharge

    Description: Modified Medical Research Council - mMRC > 0(minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T2 at 12 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T1 at 6 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T2 at 12 months from discharge

    Description: Presence and extension of radiological alterations at chest X-ray

    Measure: Presence and extension of radiological alterations at chest X-ray

    Time: T1 at 6 months from discharge

    Description: Presence and extension of radiological alterations at chest CT scan

    Measure: Presence and extension of radiological alterations at chest CT scan

    Time: T2 at 12 months from discharge
    3 COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic

    In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic

    NCT04487873
    Conditions
    1. Covid19
    2. Bronchiectasis
    MeSH:Bronchiectasis
    HPO:Bronchiectasis

    Primary Outcomes

    Description: COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.

    Measure: COVID-19 Phobia

    Time: 5 minutes

    Description: Quality of life was evaluated with Nottingham Health Profile

    Measure: Qol

    Time: 10 minutes

    Secondary Outcomes

    Description: Health anxiety was evaluated with Health Anxiety Inventory

    Measure: Health anxiety

    Time: 10 minutes

    Description: Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)

    Measure: Physical activity

    Time: 5 minutes

    Description: Quality of sleep was evaluated with Pittsburgh Sleep Quality Index

    Measure: Quality of sleep

    Time: 10 minutes

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook